An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.
Approval Alert | Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRC
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
2
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
3
FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL
4
Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC
5
